Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$7.99 USD
+0.07 (0.88%)
Updated Apr 22, 2024 11:56 AM ET
After-Market: $8.06 +0.07 (0.88%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Income Statements
Fiscal Year end for Ironwood Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 443 | 411 | 414 | 390 | 428 |
Cost Of Goods | 0 | 0 | 0 | 3 | 24 |
Gross Profit | 443 | 411 | 414 | 386 | 405 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,388 | 160 | 182 | 243 | 284 |
Income After Depreciation & Amortization | -945 | 250 | 232 | 143 | 120 |
Non-Operating Income | 19 | 10 | 0 | -5 | -25 |
Interest Expense | 22 | 8 | 31 | 29 | 37 |
Pretax Income | -948 | 252 | 201 | 109 | 59 |
Income Taxes | 83 | 77 | -328 | 3 | 0 |
Minority Interest | -29 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -1,032 | 175 | 528 | 106 | 59 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | -37 |
Net Income (GAAP) | -1,002 | 175 | 528 | 106 | 22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -944 | 252 | 234 | 147 | 126 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 2 | 4 | 6 |
Income After Depreciation & Amortization | -945 | 250 | 232 | 143 | 120 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 155.44 | 186.31 | 164.42 | 160.66 | 153.61 |
Diluted EPS Before Non-Recurring Items | -6.27 | 0.96 | 1.16 | 0.79 | 0.55 |
Diluted Net EPS (GAAP) | -6.45 | 0.96 | 3.21 | 0.66 | 0.14 |
Fiscal Year end for Ironwood Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 117.55 | 113.74 | 107.38 | 104.06 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 117.55 | 113.74 | 107.38 | 104.06 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 79.97 | 73.72 | 1,190.53 | 43.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 37.58 | 40.02 | -1,083.15 | 60.09 |
Non-Operating Income | NA | 1.19 | 1.75 | 8.76 | 7.29 |
Interest Expense | NA | 8.42 | 9.84 | 1.84 | 1.53 |
Pretax Income | NA | 30.36 | 31.93 | -1,076.22 | 65.86 |
Income Taxes | NA | 32.11 | 17.98 | 13.26 | 20.15 |
Minority Interest | NA | -0.66 | -1.37 | -27.29 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.74 | 13.95 | -1,089.48 | 45.71 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.09 | 15.32 | -1,062.19 | 45.71 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 156.01 | 186.89 | 155.37 | 154.45 |
Diluted EPS Before Non-Recurring Items | NA | 0.00 | 0.12 | 0.31 | 0.25 |
Diluted Net EPS (GAAP) | NA | 0.05 | 0.09 | -6.84 | 0.25 |